Please use this identifier to cite or link to this item:
Title: Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications
Author: Muñoz Cano, Rosa Maria
Casas Saucedo, Rocio
Valero, Antonio
Bobolea, Irina
Ribó, Paula
Mullol i Miret, Joaquim
Keywords: Al·lèrgia
Issue Date: 1-Jan-2019
Publisher: MDPI
Abstract: Platelet-activating factor (PAF) is a lipid mediator involved in several allergic reactions. It is released from multiple cells of the immune system, such as eosinophils, neutrophils, and mast cells, and also exerts its effect on most of them upon specific binding to its receptor, becoming a pleiotropic mediator. PAF is considered a potential relevant mediator in allergic rhinitis, with a key role in nasal congestion and rhinorrhoea due to its effect on vascular permeability. Interestingly, despite its potential relevance as a therapeutic target, no specific PAF inhibitors have been studied in humans. However, rupatadine, a second-generation antihistamine with dual antihistamine and anti-PAF effects has shown promising results by both blocking nasal symptoms and inhibiting mast cell activation induced by PAF, in comparison to antihistamine receptor drugs. In conclusion, the inhibition of PAF may be an interesting approach in the treatment of allergic rhinitis as part of a global strategy directed at blocking as many relevant inflammatory mediators as possible.
Note: Reproducció del document publicat a:
It is part of: Journal of Clinical Medicine, 2019, vol. 8, num. 9
Related resource:
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
12474_5808246_platelet_jcm-08-01338.pdf1.41 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons